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Pericytes, the key components of the neurovascular unit 
(NVU), are responsible for the formation, regulation and 
maintenance of the blood- brain barrier (BBB). Cerebral cap-
illaries are uniquely enriched in pericytes and degeneration 
of these cells have major contributions to the brain patho-
physiology of several neurological diseases, including stroke. 
Despite their pivotal role in the brain architecture, it remained 
unclear whether transplantation of pericytes may reconstitute 
the BBB and ultimately contribute to recovery after stroke. 
The major limitations have been the heterogeneous nature of 
pericytes and their scarcity as a cell source.
In a recent study, Sun and colleagues 1 generated pericyte- 
like cells from human- induced pluripotent stem cells (iPSCs). 
They recapitulated the developmental differentiation of peri-
cytes from cranial neural crest cells (CNC) and optimized 
previously existing protocols. This shortened differentiation 
time and the use of stable and chemically defined protocols 
is an important prerequisite for the scalability and good man-
ufacturing practice (GMP) requirements to advance from in 
vitro to preclinical and clinical in vivo cell- based studies. 
Since pericytes are contractile cells surrounding the blood 
vessels and regulate blood circulation upon neuronal activ-
ity, Sun and colleagues determined the contractile properties 
of the iPSC- derived pericytes by in vitro experiments. They 
confirmed the expression of major contractile proteins (eg 
vimentin, tropomyosin and myosin) and the pericyte's abil-
ity to compress a matrigel in a contraction assay similar to 
primary human brain vascular pericytes and aortic smooth 
muscle cells, which were used as a positive control. Next, the 
generated pericytes were transplanted through intravenous 
injections in a mouse model of transient middle cerebral ar-
tery occlusion (tMCAo) 6 hours after stroke induction. The 
transplants grafted at the site of injury, reduced brain damage 
and restored functional deficits at 3- and 7- day post- injury. 
Histological analysis of the brain tissue revealed that trans-
planted pericytes were associated with reduced brain swell-
ing, reconstruction of major protein components of the BBB 
and reduced neuronal apoptosis. Overall, this study provides 
the first evidence that transplanted iPSC- derived pericytes 
may significantly contribute to BBB reconstruction and pro-
mote functional recovery.
Since most current cell therapy strategies focus on mes-
enchymal stem cells or iPSC- derived neuronal cells, these 
findings expand the spectrum of potentially suitable cell 
sources in stroke. Major uncertainties in the field still remain 
in preclinical and clinical cell therapies about the route of 
administration. Although the authors report a relatively low 
efficiency of engraftment following systemic transplanta-
tion (only 30% of endothelial cells were surrounded by the 
transplanted pericytes at the injury site at 7 days post- injury), 
these cell numbers were sufficient to restore major compo-
nents of the damaged BBB. From a therapeutic perspective, 
on the other hand, delayed transplantation of pericytes might 
be favourable to determine the translational viability of these 
preclinical findings. Since acute transplantation of pericytes 
will require an allogeneic transplantation from a healthy 
donor, important aspects need further investigation concern-
ing the immunogenicity of pericytes. Fortunately, current 
advancements in genetic engineering towards universal and 
hypoimmunogenic iPSC may overcome this limitation in the 
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near future.2 Moreover, it remains unclear whether the ob-
served beneficial effects after stroke are permanent due to the 
relatively short- time course. Many regenerative processes, 
for example, neo- angiogenesis have been reported to have 
only transient effects following stroke and be less relevant 
for long- term recovery.3 Since the functional tests have been 
performed at relatively early time points, these findings most 
likely rather indicate protective than regenerative effects of 
pericytes; and their long- term benefit remains to be eluci-
dated. Recent studies have also described a dual role of peri-
cytes in stroke recovery; similar as previously observed for 
astrocytes and microglia.4,5 Apart from their beneficial role 
to maintain BBB integrity, subclasses of pericytes can con-
tribute to scar formation and inhibit axonal regeneration in 
major brain injuries including stroke.6,7 A determinantal role 
of pericytes has also been observed acutely after ischaemia. 
Pericytes remained contracted causing capillary constriction 
and reduced blood flow to the injured brain.8 Future research 
might dissect the heterogeneous nature of the transplanted 
iPSC- derived pericyte- like cells and their contribution to 
stroke recovery.
Apart from stroke, these findings are also highly rele-
vant to other major neurological disorders with a vascular 
component such as Alzheimer's disease (AD), vascular de-
mentia (VD), spinal cord injury (SCI) or traumatic brain in-
jury (TBI).9 It has become apparent that pericyte loss is an 
important contributor of vascular dysfunction and leads to 
worsening of disease pathophysiology and neurodegenera-
tion in AD patients.10,11 Recent findings further highlighted 
that degeneration of pericytes has a direct influence on the 
cognition, independent of the main pathological hallmarks 
of the AD.12 Still lacking a disease- modifying therapy, the 
AD field requires better characterization of the disease with 
the advancements in diagnostics and innovative solutions to 
tackle the complex underlying pathology. The findings by 
Sun and colleagues encourage future research to investigate 
the therapeutic effects of pericyte- based cell therapy in mouse 
models of AD, which may become especially powerful and 
clinically viable with the current advancements of CSF and 
blood biomarkers for BBB damage.12 However, it is import-
ant to note that translating the results from an acute vascular 
dysfunction model such as stroke to a chronic impairment as 
in the case of AD would require further optimization espe-
cially for the delivery route, the cell number and time point 
of transplantation (Figure 1).
Despite the need for further optimization and future con-
firmatory studies, regeneration of the neurovascular unit with 
cell- based therapies has shown to have a great potential to 
restore neuronal integrity and functionality. The promising 
results from the stroke model illustrate that the efficacy of the 
vascular repair could be tested with further preclinical studies 
in other neurological disorders. Overall, therapeutic strate-
gies aiming at restoring cerebrovascular health could pave a 
new way forward to help millions of patients suffering from 
neurological diseases.
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F I G U R E  1  Pericyte- based cell therapy following brain injury. (1) Transplantation of iPSC- derived pericyte- like cells restores blood- brain 
barrier (BBB), reduces neuronal cell death and improves recovery in a mouse model of stroke. (2) A potential translational approach will consist of 
the generation of pericyte- like cells from a donor's reprogrammed primary blood cells. These cells will be injected systemically to stroke patients 
that exhibit severe damage of the BBB. (3) Patients with major neurological disease include acute injuries, for example spinal cord injury, traumatic 
brain injury or a chronic injury, for example Alzheimer's disease and vascular dementia. These patients may also benefit from pericyte- based cell 
therapy since all of these injuries also exhibit BBB disruption and pericyte degeneration as an important hallmark
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